• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

Factor XIII Deficiency

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.


Replacement of factor XIII is used to treat bleeding or prevent bleeding during or immediately after surgery (perioperative bleeding). It is also used to prevent recurrent bleeding. The success of therapy must always be monitored by assessing factor XIII levels.

Prophylactic factor XIII replacement therapy
This therapy is mainly used in patients with inherited factor XIII deficiency who are at risk of intracranial bleeding and/or recurrent miscarriages. It is recommended that patients with clinically significant bleeding should start receiving factor XIII replacement therapy in childhood to reduce the risk of severe, life-threatening bleeds.18 Levels of factor XIII above 3–5% of normal are usually enough to prevent spontaneous bleeding.19

Factor XIII replacement agents
The treatment of choice for factor XIII deficiency is plasma-derived factor XIII concentrate, which is a virus inactivated product.19 Fresh frozen plasma (FFP) and cryoprecipitate, which contain a low concentration of a mixture of clotting factors, are also used for factor XIII replacement.18

CSL Behring products for Factor XIII deficiency treatment

Package Inserts

Product Websites

Corifact.com (United States)

Not all products are available in every country. To learn what products are available in your country, visit your CSL Behring country site.

Last Updated: 4/23/2015 3:18 PM
  • E-mail
  • Print
  • Share